AllianceBernstein’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$74.3M Sell
523,533
-31,961
-6% -$4.24M 0.02% 478
2025
Q4
$78.8M Sell
555,494
-62,635
-10% -$9.07M 0.02% 477
2025
Q3
$86.8M Buy
618,129
+33,698
+6% +$4.57M 0.03% 457
2025
Q2
$73.5M Buy
584,431
+8,259
+1% +$947K 0.02% 496
2025
Q1
$63.7M Sell
576,172
-1,444
-0.2% -$183K 0.02% 519
2024
Q4
$78.8M Sell
577,616
-59,298
-9% -$7.33M 0.03% 468
2024
Q3
$73.4M Buy
636,914
+15,049
+2% +$2.06M 0.02% 501
2024
Q2
$85.6M Buy
621,865
+461,642
+288% +$63.3M 0.03% 453
2024
Q1
$22.1M Sell
160,223
-13,405
-8% -$1.83M 0.01% 837
2023
Q4
$22.9M Buy
173,628
+24,868
+17% +$2.86M 0.01% 830
2023
Q3
$16.7M Buy
148,760
+10,677
+8% +$1.12M 0.01% 909
2023
Q2
$13M Sell
138,083
-13,266
-9% -$1.3M 0.01% 1014
2023
Q1
$15.3M Sell
151,349
-15,512
-9% -$1.61M 0.01% 930
2022
Q4
$19.9M Buy
166,861
+11,693
+8% +$1.37M 0.01% 831
2022
Q3
$16.5M Buy
155,168
+6,541
+4% +$664K 0.01% 895
2022
Q2
$14.5M Sell
148,627
-36,859
-20% -$3.4M 0.01% 971
2022
Q1
$17.4M Buy
185,486
+21,984
+13% +$1.86M 0.01% 987
2021
Q4
$13.9M Sell
163,502
-7,748
-5% -$713K ﹤0.01% 1093
2021
Q3
$16.4M Buy
171,250
+18,279
+12% +$1.73M 0.01% 1018
2021
Q2
$14.9M Sell
152,971
-5,975
-4% -$573K 0.01% 1059
2021
Q1
$15.5M Buy
158,946
+100,678
+173% +$10.6M 0.01% 1016
2020
Q4
$5.58M Sell
58,268
-639,914
-92% -$61.8M ﹤0.01% 1421
2020
Q3
$67.1M Sell
698,182
-190,677
-21% -$22.1M 0.04% 460
2020
Q2
$108M Sell
888,859
-244,961
-22% -$27.1M 0.06% 285
2020
Q1
$98.1M Sell
1,133,820
-106,113
-9% -$10.4M 0.07% 259
2019
Q4
$133M Sell
1,239,933
-10,702
-0.9% -$1.12M 0.08% 250
2019
Q3
$113M Buy
1,250,635
+47,231
+4% +$4.41M 0.07% 276
2019
Q2
$102M Buy
1,203,404
+98,945
+9% +$8.12M 0.06% 303
2019
Q1
$97.3M Buy
1,104,459
+34,243
+3% +$2.86M 0.06% 308
2018
Q4
$76.4M Sell
1,070,216
-37,978
-3% -$3.64M 0.06% 326
2018
Q3
$136M Sell
1,108,194
-56,706
-5% -$6.43M 0.09% 229
2018
Q2
$114M Sell
1,164,900
-108
-0% -$9.67K 0.08% 259
2018
Q1
$96.6M Buy
1,165,008
+215,680
+23% +$18.2M 0.07% 298
2017
Q4
$73.7M Sell
949,328
-56,319
-6% -$3.84M 0.05% 393
2017
Q3
$61.6M Buy
1,005,647
+48,972
+5% +$2.58M 0.05% 429
2017
Q2
$44M Buy
956,675
+28,660
+3% +$1.39M 0.03% 513
2017
Q1
$40.2M Sell
928,015
-95,427
-9% -$4.09M 0.03% 522
2016
Q4
$39.6M Buy
1,023,442
+147,393
+17% +$6.67M 0.03% 516
2016
Q3
$44.4M Sell
876,049
-228,466
-21% -$11.4M 0.04% 482
2016
Q2
$50.2M Buy
1,104,515
+957,289
+650% +$44.1M 0.04% 416
2016
Q1
$5.82M Buy
147,226
+4,680
+3% +$186K ﹤0.01% 998
2015
Q4
$8.06M Sell
142,546
-1,700
-1% -$86.4K 0.01% 911
2015
Q3
$5.74M Buy
144,246
+100
+0.1% +$4.83K ﹤0.01% 1008
2015
Q2
$6.88M Buy
144,146
+8,100
+6% +$343K 0.01% 987
2015
Q1
$5.4M Buy
136,046
+10,200
+8% +$365K ﹤0.01% 1087
2014
Q4
$2.81M Hold
125,846
﹤0.01% 1478
2014
Q3
$1.97M Hold
125,846
﹤0.01% 1726
2014
Q2
$1.87M Sell
125,846
-104
-0.1% -$1.47K ﹤0.01% 1824
2014
Q1
$2.03M Sell
125,950
-6,964
-5% -$119K ﹤0.01% 1702
2013
Q4
$1.24M Buy
132,914
+538
+0.4% +$5.25K ﹤0.01% 2032
2013
Q3
$1.5M Sell
132,376
-165
-0.1% -$2.27K ﹤0.01% 1887
2013
Q2
$1.77M Buy
+132,541
New +$1.63M ﹤0.01% 1692

Other funds holding NBIX

AllianceBernstein's NBIX Position: Q1 2026 in Review

AllianceBernstein reduced its Neurocrine Biosciences (NBIX) stake by 5.8% in Q1 2026, selling an estimated $4.24M and leaving 523,533 shares worth $74.3M. The position accounts for 0.02% of the portfolio, ranked #478.

AllianceBernstein first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $136M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • AllianceBernstein held 523,533 shares of Neurocrine Biosciences worth $74.3M as of Q1 2026.
  • AllianceBernstein sold 31,961 Neurocrine Biosciences shares in Q1 2026, an estimated $4.24M.
  • Neurocrine Biosciences made up 0.02% of AllianceBernstein's portfolio in Q1 2026, its #478 holding.
  • AllianceBernstein first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • AllianceBernstein's Neurocrine Biosciences position peaked at $136M in Q3 2018.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.